Favorable News Coverage Somewhat Unlikely to Affect Immutep (NASDAQ:IMMP) Stock Price

Media stories about Immutep (NASDAQ:IMMP) have been trending positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immutep earned a news impact score of 0.26 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 48.3248237798175 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Immutep in a report on Thursday, November 9th.

Immutep (NASDAQ IMMP) traded down $0.01 on Thursday, hitting $1.85. The stock had a trading volume of 29,800 shares, compared to its average volume of 42,143. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.22. Immutep has a 1 year low of $1.25 and a 1 year high of $3.24.

COPYRIGHT VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Affect Immutep (NASDAQ:IMMP) Stock Price” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/immutep-immp-receiving-positive-news-coverage-analysis-shows.html.

About Immutep

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply